{
    "id": 7523,
    "fullName": "AR W742L",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "AR W742L (also referred to as W741L) lies within the ligand-binding domain of the Ar protein (PMID: 25563847). W742L results in relaxation of Ar ligand-specificity, and the ability to be aberrantly activated by the antiandrogen bicalutamide in cell culture (PMID: 12517791, PMID: 20878136).",
            "references": [
                {
                    "id": 3015,
                    "pubMedId": 12517791,
                    "title": "Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12517791"
                },
                {
                    "id": 3013,
                    "pubMedId": 20878136,
                    "title": "The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20878136"
                },
                {
                    "id": 3014,
                    "pubMedId": 25563847,
                    "title": "Switching and withdrawing hormonal agents for castration-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25563847"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 367,
        "geneSymbol": "AR",
        "terms": [
            "AR",
            "AIS",
            "AR8",
            "DHTR",
            "HUMARA",
            "HYSP1",
            "KD",
            "NR3C4",
            "SBMA",
            "SMAX1",
            "TFM"
        ]
    },
    "variant": "W742L",
    "createDate": "06/11/2015",
    "updateDate": "11/25/2018",
    "referenceTranscriptCoordinates": {
        "id": 146273,
        "transcript": "NM_000044",
        "gDna": "chrX:g.67717529G>T",
        "cDna": "c.2225G>T",
        "protein": "p.W742L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2383,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AR W741L conferred resistance to Casodex (bicalutamide) in prostate cancer cells in culture, via a switch of Casodex (bicalutamine) from androgen receptor antagonist to agonist (PMID: 12517791).",
            "molecularProfile": {
                "id": 7399,
                "profileName": "AR W742L"
            },
            "therapy": {
                "id": 1507,
                "therapyName": "Bicalutamide",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3015,
                    "pubMedId": 12517791,
                    "title": "Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12517791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7399,
            "profileName": "AR W742L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 146273,
            "transcript": "NM_000044",
            "gDna": "chrX:g.67717529G>T",
            "cDna": "c.2225G>T",
            "protein": "p.W742L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}